HIF1A and myeloproliferative neoplasm: Pharmacological inhibition and knockdown HIF-1α in JAK2V617F+ cells lead to impaired growth and survival, induced apoptosis, and cell cycle arrest, specifically in JAK2V617F+ cells, highlighting HIF-1α as a potential therapeutic target in JAK2V617F+ MPN [135].